Launchpad Therapeutics

Launchpad Therapeutics is a precision oncology company focused on antibodies, dedicated to developing an early-stage portfolio of mutation-selective antibody projects supported by AI-driven and structure-based drug design. Launchpad's mission is to deliver novel monoclonal antibody (mAb) designs from sequence to structure to function. Comprised of a team of experienced drug hunters, computational scientists, and simulation experts, Launchpad aims to unlock the value of early-stage antibody projects spun out from Black Diamond Therapeutics' MAP (Mutation-Allostery-Pharmacology) drug discovery engine. Launchpad’s platform is uniquely capable of delivering cancer cell-specific antibodies.